Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
Australia and New Zealand have established themselves as ideal locations to host clinical trials due to their diverse participant populations, sophisticated healthcare and research environments as well as government backed support. Both countries have adopted the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) to ensure all trials collect high quality and credible data that is internationally recognised.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing.
Now, three of the largest clinical trial organisations across Australia and New Zealand have united to form Momentum Clinical Research – an end-to-end clinical research network with sites that have been operating for over 20 years. Combined, they have 13 site locations across the Trans-Tasman and are set to open more locations to allow more studies to take place and enable everyday people to access new and emerging therapies.
In February 2024, New Zealand’s renowned P3 Research joined forces with Australia’s AusTrials and Holdsworth House to form Momentum Clinical Research. The combined entity can now provide sponsors a single point of contact for their current 13 sites across the two countries,
Momentum Clinical Research aims to provide quick responses to feasibility requests, faster study starts and accelerated recruitment – all leading to the delivery of high-quality results for Phase 1b-IV clinical trials. Momentum Clinical Research has become the only Trans-Tasman network of clinical trial sites.
Australian Health Journal spoke with Aus Trials Research Director, Dr Munro Neville, on the Australian clinical trial landscape more broadly and reasons for creating a Trans-Tasman clinical research organisation.
Further growth in the industry is expected, with the Australian Government having pledged $750 million to increase clinical trial activity between 2022-2032. Similarly, the New Zealand Government has invested $98 million into health research funding from 2017-2027 to facilitate the conduct of clinical trials.
-
Landmark Australian-led study revises thresholds to diagnose and treat anaemia
In 2014, WEHI researchers began a study at the request of the World Health Organization (WHO), to formally review its global anaemia guidelines that were last updated in 1968.
Study lead and Acting WEHI Deputy Director, Professor Sant-Rayn Pasricha, speaking to Australian Health Journal said while anaemia can be diagnosed by measuring the amount of haemoglobin in the blood, there is currently no consensus on the thresholds that should be used to define the condition. -
World-first clinical trial improves patient outcomes for kidney transplants
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Pharmacy led men’s urological health
Men’s urological needs refer to the medical and surgical conditions that affect the male urinary tract system and reproductive organs.
A urologist can address these concerns, however a pharmacy-led model of care developed by Brad Butt, called Mens Health Downunder has offered an alternative to certain urological needs of the male adult population over the past 10 years.
Australian Health Journal met with Brad to hear about his journey, Mens Health Downunder and the impact the pharmacy-led model of care has had on patient’s urological as well as mental health.
